Erypeg 30 Injection contains Pegylated Recombinant Human Erythropoietin (30 mcg), a biologically engineered erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease (CKD), chemotherapy, or other medical conditions resulting in insufficient red blood cell production. The pegylation process extends the half-life of erythropoietin, allowing for less frequent dosing while maintaining effective stimulation of erythroid progenitor cells in the bone marrow. Erypeg 30 Injection is administered via subcutaneous or intravenous routes under medical supervision, with dosage individualized based on patient response and hemoglobin levels. It is indicated to reduce the need for blood transfusions by promoting endogenous erythropoiesis. Prior to initiation, patients should be evaluated for iron status, as adequate iron stores are essential for optimal therapeutic response. Monitoring of hemoglobin concentration, blood pressure, and potential adverse effects such as hypertension, thromboembolic events, and hypersensitivity reactions is critical during treatment. Erypeg 30 Injection should be used cautiously in patients with uncontrolled hypertension or a history of stroke or cardiovascular disease. This product is contraindicated in patients with hypersensitivity to erythropoietin or any component of the formulation. Proper storage and handling are required to maintain stability and efficacy.